A cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapy

Abstract

The purpose of this study is to conclude as to whether it is cost-effective to introduce genotyping in the Norwegian clinical practice in the case of acute coronary syndrome, as a guide of pharmacotherapy decision making after a percutaneous coronary intervention.